Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

Jean-Yves Blay, Q. Devin, Florence Duffaud, Maud Toulmonde, Nelly Firmin, Olivier Collard, Emmanuelle Bompas, Benjamin Verret, Isabelle Ray‐Coquard, Sébastien Salas, Clémence Henon, Charles Honoré, Mehdi Brahmi, Armelle Dufresne, Marc Pracht, Alice Hervieu, Nicolas Penel, François Bertucci, María Rios, Esma Saâda-Bouzid, Pauline Soibinet, David Pérol, Sylvie Chabaud, Antoîne Italiano, Axel Le Cesne